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Abstract: 
"Hepatitis C virus (HCV) is the most common chronic bloodborne infection in the United 
States." (Centers for Disease, 1998) It is estimated that 3.9 million to 5 million of the US 
population is infected with tbis virus. Transmission of HCV occurs primarily to those 
who have been exposed to large or repeated direct contact with infected blood. Persons 
at risk of exposure include those who have injected drug use, blood transfusions before 
1992, solid organ transplantation from infected donors, unsafe medical practices, and 
occupational exposures to infected blood, and birth to an infected mother, and sex with an 
infected person, high-risk sexual practices, and possibly intranasal cocaine use. Hepatitis 
C is a common cause of cirrhosis, hepatocellular carinoma (HCC), and the most common 
reason for liver transplantation. 
Current recommendations from the Center for Disease Control, National Institutes 
of Health, and United States Preventative Service Task Force (USPSTF) disagree on who 
is considered high risk for infection and who should be tested for HCV. Health care 
costs predictions for hepatitis C in the absence of liver transplant have been high. 
Research, recommendations, and policies need to be addressed to fight this Public Health 
Problem. 
We stand at the precipice of a grave threat to our public health ... It afflicts people from 
all walks of life, in every state, in every country. And unless we do something about it 
soon, it will kill more people than AIDS 
-C. Evertt Koop Former Surgeon General of the United States. 
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Introduction 
Hepatitis means inflammation of the liver. Inflammation of the liver can happen 
for several reasons. One reason is viral hepatitis C infection. "Following the identification 
of hepatitis A and hepatitis B, this disorder was categorized in 1974 as 'non-A, non-B 
hepatitis.' In 1989, the hepatitis C virus was identified and found to account for the 
majority of those patients with non-A, non-B hepatitis."(National Institutes, 2002) 
"Hepatitis C virus (HCV) infection is the most common chronic bloodbome infection in 
the United States." (Center for Disease, 1998) "Data from the Third National Health and 
Nutrition Examination Survey (NHANES III), conducted during 1988-1994, have 
indicated that an estimated 3.9 million (1.8%) of Americans are infected with Hepatitis 
C." (Center for Disease, 1998) "Chronic liver disease is the tenth leading cause of death 
among adults in the United States, and accounts for 25,000 deaths annually, or 
approximately 1% of all deaths."(Center for Disease, 1998) "It is one of the leading 
causes of chronic liver disease morbidity and mortality and the most common indication 
for liver transplantation." (Alter et al., 2004) "It is a common cause of cirrhosis and 
hepatocellular carcinoma (HCC) as well as the most common reason for liver 
transplantation."(National Institutes, 2002). Hepatitis C and those affected with hepatitis 
C are a significant burden on our health care system. Public health and other prevention 
programs must be initiated. 
This paper will address case definition of the disease, the epidemiology, the 
background, and current data and disease management and treatment, and demonstrate 
how hepatitis C is a public health problem. This paper will also address current 
recommendations, look at the barriers and benefits and disadvantages to testing, look at 
3 
health care cost predictions and economic impact analysis, and review current programs 
within the United States. Based on recommendations and research suggested policy 
changes, specifically for hepatitis C in the United States, will be addressed and 
recommended. 
According to the Center for Disease Controls Viral Hepatitis C website 
(http://www.cdc.gov/ncidod/diseases/hepatitis/c/lbtinfo.htm), the discovery of HCV was 
reported in 1989, and the first blood test for HCV became available in May 1990, which 
identified most, but not all, donors infected with HCV. Improved blood tests were put 
into use in July of 1992. This website also suggests that an individual should be tested if 
notified of the possibility of having received blood that possibly contained the hepatitis C 
virus or if an individual received blood before July 1992. 
Hepatitis C Case Definition 
Hepatitis C can be categorized and diagnosed into two types of infection, acute 
(short term) and chronic (long term). Acute infections are those that are new, usually 
within 6 months after exposure. Chronic are infections that are acquired longer than 6 
months ago. "After initial exposure, HCV RNA can be detected in blood within 1 to 3 
weeks and is present at the onset of symptoms."(National Institutes, 2002) According to 
the National Digestive Disease Information Clearinghouse, "Acute hepatitis Cis 
diagnosed on the basis of symptoms such as jaundice, fatigue, and nausea, along with 
marked increases in serum alanine aminotransferase ALT (usually greater than 10-fold 
elevation), and presence of anti-HCV or de novo development of anti-HCV." (National 
Digestive, 2003) The diagnosis of acute hepatitis Cis very difficult because anti-HCV is 
not always present when the patient develops symptoms and sees the physician. 
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Chronic Hepatitis C/Background Data 
Hepatitis C "accounts for about 15 percent of acute viral hepatitis, 60 to 70 
percent of chronic hepatitis, and 50 percent of cirrhosis, end-stage liver disease, and liver 
cancer." (National Digestive, 2003) A distinct and major characteristic of hepatitis Cis 
its tendency to cause chronic liver disease. "At least 75 percent of patients with acute 
hepatitis C ultimately develop chronic infection, and most of these patients have 
accompanying chronic liver disease." (National Digestive, 2003) Often those witb 
chronic hepatitis C do not display signs or symptoms of liver disease or display any 
abnormality in serum liver enzymes. Due to this frequent lack of symptoms, hepatitis C is 
difficult to discern without the help of screening measures and more education strategies. 
"Chronic hepatitis C can cause cirrhosis, liver failure, and liver cancer. Researchers 
estimate that at least 20 percent of patients with chronic hepatitis C develop cirrhosis, a 
process that takes at least 10 to 20 years. After 20 to 40 years, a smaller percentage of 
patients with chronic disease develop liver cancer. Liver failure from chronic hepatitis C 
is one of tbe most common reasons for liver transplants in the United States. Hepatitis C 
is the cause of about half of the cases of primary liver cancer in the developed world." 
(National Digestive, 2003) 
Treatment 
There is treatment for Hepatitis C and it is usually treated with anti-viral therapy. 
More than 10 years ago alpha interferon was approved to treat hepatitis C. "At the 
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present time, the optimal regimen appears to be a 24- or 48-week course of the 
combination of pegylated alpha interferon and ribavirin." (National Digestive, 2003) 
"Alpha interferon is a host protein that is made in response to viral infections and natural 
antiviral activity." (National Digestive, 2003) "Pegylation changes the uptake, 
distribution, and excretion of interferon, prolonging its half-life." (National Digestive, 
2003) Pegylation changes the treatment in that the injections can be given once weekly 
with a constant level of interferon in the blood, whereas standard interferon was given 3 
times a week with intermittent and fluctuating levels. "Ribavirin is an oral antiviral agent 
that has activity against a broad range of viruses." (National Digestive, 2003) "By itself, 
ribavirin has little effect on HCV, but adding it to interferon increases the sustained 
response rate by two to threefold." (National Digestive, 2003) Two forms of 
peginterferon have been developed, one called Pegasys which was developed by 
Hoffman La Roche; and peginterferon alfa-2b developed by Scheing-Plough Corporation. 
"Ribavirin is an oral medication, given twice a day in 200-mg capsules for a total daily 
dose based on body weight." (National Digestive, 2003) These medications used in 
combination "have lead to improvements in serum ALT levels and disappearance of 
detectable HCV RNA in up to 70 percent of patients." (National Digestive, 2003) 
Duration of treatment is determined by HCV genotype. "Patients with genotype 2 and 3 
have a high rate of response to combination treatment and the 24 week course is 
equivalent to those in a 48 week course." (National Digestive, 2003) "In contrast, 
patients with genotype 1 have a lower rate of response to combination therapy (40 to 45 
percent), and a 48 week course yields a significantly better sustained response rate." 
(National Digestive, 2003) 
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Epidemiology (Person, Place, Time) 
The epidemiologic characteristics of those affected with HCV infection show that 
it "occurs among persons of all ages, but the highest incidence of acute hepatitis C is 
found among persons aged 20-39 years, and males predominate slightly." (Center for 
Disease, 1998) "In the general population, the highest prevalence rates of HCV infection 
are found among persons aged 30-49 years and among males." (Center for Disease, 1998) 
But according to the NIH Consensus Development Program: Management of Hepatitis C: 
2002, "Currently, persons aged 40-59 years have the highest prevalence of HCV 
infection, and in this age group, the prevalence is highest in African Americans (6.1 
percent)." (National Institutes, 2002) According to Armstrong et al, "Most were born 
between 1945 and 1964 and can be identified witb current screening criteria." 
(Armstrong et al., 2006) "The genetic diversity of HCV circulating in the United States 
and the pattern of age-specific prevalence both suggest that the incidence of infection 
increase substantial! y in the 1960s and 1970s and peaked in the 1980s." (Armstrong et a!, 
2006) "According to data for the Department of Veterans Affairs, veterans of Vietnam 
between the ages of 40 to 55 years are believed to be at particularly high risk" (Instone, 
Gilbert, & Mueller, 2003) "This is based on studies suggesting prevalence rates ranging 
from 3% to 35%." (Instone eta!., 2003) HCV transmission occurs primarily to those 
persons that have been exposed to large or repeated direct contact with percutaneous or 
infected blood. "This exposure exists in the contexts of injection drug use, blood 
transfusions before 1992, solid organ transplantation from infected donors, unsafe 
medical practices, and occupational exposure to infected blood, and birth to an infected 
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mother, and sex with an infected person, high-risk sexual practices, and possibly 
intranasal cocaine use." (National Institutes, 2002) Luckily in mid 1992 a more sensitive 
test for antibodies to HCV was introduced and has virtually eliminated the risks that 
transfusions and organ transplants presented in the past. "High HCV seroprevalence 
rates (from15-50 percent) have occurred in specific subpopulations, such as the homeless, 
incarcerated persons, injection drug users, and persons with hemophilia who were treated 
with clotting factors before 1992." (National Institiutes, 2002) The National Health and 
Nutrition Examination Survey (NHANES) "is a population based household survey, it 
does not include certain groups with a substantially increased prevalence of infection 
such as persons who are incarcerated, homeless, or institutionalized." (National Institutes, 
2002). According to the website http://www.epidemic.org/theFacts/theEpidemic, it is 
suspected that there are currently more than 5 million people in the US infected with 
Hepatitis C. 
"This makes it one of the greatest public health threats faced in this century, and 
perhaps one of the greatest threats to be faced in the next century. Without rapid 
intervention to contain the spread of the disease, the death rate from hepatitis C 
will surpass that from AIDS by the tum of the century and will only get worse." 
(C. Everett Koop, 1998) 
The good news is that we have seen the incidence of newly acquired hepatitis C infection 
has diminished in the United States. "This decline is largely due to a decrease in cases 
among IDUs for reasons that are unclear and, to a lesser extent to testing of blood donors 
for HCV" (National Institutes, 2002) One would suspect that risk reduction practices 
taught in the HIV epidemic have also helped decrease transmission of HCV in IDU' s 
today. 
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Current Reconunendations: 
The Centers for Disease Control have a National Hepatitis C Prevention Strategy 
that includes of the following elements: 
• 
• 
• 
"Communication of information about hepatitis C to health care and 
public health professionals and education of the public and persons at risk 
for infection; 
Integration of hepatitis C prevention and control activities into state and 
local public health programs to identify, counsel, and test persons at risk 
for HCV infection; provide referral for medical evaluation of those found 
to be infected; and conduct outreach and community-based activities to 
address practices that put people at risk for HCV infection; 
Surveillance to monitor acute and chronic disease trends and evaluate the 
effectiveness of prevention and medical care activities; and epidemiologic 
and laboratory investigations to better guide prevention efforts." (Centers 
for Disease, 2006) 
The NIH Consensus Development Program website 
http://consensus.nih.gov/2002/200HepatitisC2002116htm.htm, lists twelve 
recommendations in regard to the management of hepatitis C: 
• 
• 
• 
• 
• 
• 
• 
Educate the American public on the transmission of HCV in order to 
better identify affected individuals and to institute preventive measures. 
Develop reliable, reproducible, and efficient culture systems for 
propagating HCV and expand basic research in the pathogenic 
mechanisms underlying hepatitis fibrosis. 
Promote the standardization and wide availability of diagnostic tests for 
HCV infection and its complications, leading to early diagnosis and the 
implementation of appropriate treatment practices. 
Promote the establishment of screening tests for all groups at high risk of 
HCV infection, including IDU's and incarcerated individuals. 
Expand the delineation of disease manifestations, noninvasive tests, and 
the role of liver biopsy, so that the application of current treatment 
practices may be refined. 
Establish a Hepatitis Clinical Research Network for the purpose of 
conducting research related to the natural history, prevention, and the 
treatment of hepatitis C. 
Organize Randomized Control Trials to extend treatment to special 
populations not represented in current clinical trials and to determine the 
applicability of accepted anti viral drug combinations to populations such 
as children and adolescents, and patients with acute hepatitis. Effective 
approaches are needed for drug users receiving drug treatment, alcohol 
abusers, prisoners, patients with stabilized depression, those with co-
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infection with HIV, patients with compensated cirrhosis, and HCV 
infections in transplant recipients. Such efforts should lead to decreased 
mobidity and mortality from the disease, as well as a decrease in the 
reservoir of disease. 
• Institute measures to reduce transmission of HCV among IDU' s, including 
providing access to sterile syringes through needle exchange, physician 
prescription, and pharmacy sales; and expanding the Nation's capacity to 
provide treatment for substance abuse. Physicians and pharmacists should 
be educated to recognize that providing IDUs with access to sterile 
syringes and education in safe injection practices may be lifesaving. 
• Decrease the transmission of HCV from mother-to-infant by evaluating 
strategies that interrupt this type of transmission. 
• Compare new therapies to current treatments in non-responders, to include 
not just antiviral agents but also combinations of antifibrotic drugs, 
immunomodulatory agents, and alternative therapies." 
• Encourage a comprehensive approach to promote the collaboration among 
health professionals concerned with management of addiction, primary 
care physicians, and specialist involved in various aspects of HCV to deal 
with the complex societal, medical, and psychiatric issues of IDUs 
afflicted by the disease. 
• Seek appropriate support from governmental agencies and the private 
sector to address urgent research questions concerning the epidemiology 
and treatment of this disease. (National Institutes, 2002) 
"When there is adequate evidence to determine the magnitude of the net benefit of 
delivering a preventive service, the USPSTF assigns 1 of 4 letter grades, A, B, C, D; 
which indicate that the net benefit is substantial, moderate, small, or none, respectively." 
(Calonge, 2004) 
These recommendations are communicated by letter grades that reflect the quality 
of evidence and the magnitude of net health benefit expected from delivering the 
preventive service. When the USPSTF finds insufficient evidence to determine 
the balance of health benefits or harms of delivering a preventive service, 
because of a lack of studies, poor-quality studies, or good-quality studies with 
conflicting results, the USPSTF assigns the service an I letter grade." 
(Calonge, 2004) 
The U.S. Preventative Services Task Force (USPSTF) recommends against routine 
screening for hepatitis C virus (HCV) infection in asymptomatic adults who are not at 
increased risk (general population) for infection (USPSTF Statement, 2004) and gave it a 
rating D recommendation. The USPSTF found insufficient evidence to recommend for 
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or against routine screening for HCV infection in adults at high risk infection and gave it 
an I recommendation Therefore, an "I" recommendation is a call for additional research 
that would provide the appropriate evidence base to make either a positive or negative 
recommendation. 
In summary, both the NIH and CDC recommend screening for high risk for HCV 
infection but the USPSTF finds insufficient evidence to support these recommendations. 
"Both recommend screening for users of injection drugs, hemodialysis patients, and 
recipients of transfusions or organs (CDC recommendations cover the years before 1992, 
and the NIH recommendations cover the years before 1990.)" (US Preventative, 2004) 
"In addition, the NIH panel recommends screening for individuals with multiple sex 
partners; spouse or household contacts of HCV infected patients, and those who share 
instruments of intranasal cocaine use. The CDC recommends screening for children born 
to mothers infected with HCV, those who received clotting factor concentrates before 
1987, those with occupational exposure to HCV-positive blood, and patients with 
persistently abnormal alanine aminotransferase levels." (US Preventative, 2004) The 
CDC also has a list of groups whom screening is uncertain which includes groups like 
persons who use intranasal cocaine and other non-injecting illegal drugs, persons with 
history of tattooing or body piercing, recipients of transplanted tissue, those with history 
of multiple sex partners or sexually transmitted diseases, and long-term steady partners of 
HCV -positive persons. It is understandable why the U.S. Preventive Services Task Forces 
could not give a recommendation when the two leading agencies in the United States 
can't even agree who is at high risk. 
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Graph I lists the Risk Factors.for Acute Hepatitis C United States, 1990-1995. 
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Where are the appropriate places for hepatitis testing to be conducted? The 
rationale for integrating hepatitis testing into IDV counseling and testing sites and STD 
services are that there is overlap of disease risk by populations seen by these facilities. 
With similar populations at risk, integrating services increases the availability of multiple 
services to high risk clients and the opportunity to offer multiple services. Currently, the 
existing infrastructure is available. Duplication of services in alternative sites is more 
costly and less efficient. Furthermore, meeting the comprehensive needs of the client 
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results in better customer service and better uses of resources. The integration of services 
maximizes the fiscal uses of all the resources. 
The positive aspect of testing HCV high-risk individuals they will know their 
disease status. By incorporating HCV testing into the already developed counseling, 
testing, and referral process for HlV testing, education about hepatitis C transmission can 
be given before and after testing. Thus if individuals test positive, the argument can be 
made that they can protect others from disease. Those with positive results can also be 
offered harm reduction techniques to work on decreasing negative impact behaviors such 
as the intake of alcohol and drugs, which may speed up the negative effects caused by the 
virus. If individuals test negative they will be given the information needed for harm 
reduction (things that they can do to decrease their risk). Furthermore, many public 
health programs integrate STD and HlV services with hepatitis testing making it a great 
screening tool for other diseases with overlapping risks. Many programs also have 
services to vaccinate for hepatitis A and B, which protects hepatitis C infected individuals 
from acquiring other viruses that attack the liver. HCV testing can also be an opportunity 
to educate, inform, and refer individuals to support groups, medical care, and other drug 
and alcohol groups within communities. Diagnosis of Hepatitis C may be a motivator for 
those clients to limit drug and alcohol intake, which they might not have done if they did 
not test. The USPTF states 
"persons with HCV infection identified through targeting testing can seek medical 
evaluation to determine the severity of their disease, to consider treatment, and to 
make lifestyle changes that could reduce the likelihood of disease progression. In 
addition, people who know their status can avoid infecting others." (Alter et a!., 
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2004) 
The arguments against HCV testing are varied and include the fact that funding 
for HCV testing is limited and organizations may not have, or rely on the already created 
HN, STD, and immunization infrastructures to provide services. Many individuals also 
question if it is ethical to test for HCV if you do not have strong linkages to care and 
treatment, especially for the indigent within your community. Another argument against 
utilizing HN testing sites is the ethics concerning use of HN prevention dollars and 
staffs time to address other diseases. Will HCV testing stretch and overburden our staff 
and clinicians to learn another disease? Is testing a disservice to the community and 
clients if it isn't sustainable independently? Furthermore, many clients at risk are also 
dealing with issues of addiction. Can they handle another health challenge? Are there 
community resources to address the added mental burden of infection knowledge? 
Another barrier to an individual considering testing, may be the realization of the 
extremely high cost of treatment and the recommend 6 months to 1 year of treatment. 
Other potential harms of screening identified by the USPTF relate to false-positive tests 
results. For example knowledge of (false) positive testing may cause anxiety, shared 
knowledge of HCV status may cause discrimination, and medical evaluations could cause 
complications from further evaluations such as liver biopsy. National Digestive Disease 
Information Clearinghouse also stated that with treatment there are several side effects. 
"In 10 percent of patients common side effects include fatigue, muscle aches, headaches, 
nausea and vomiting, skin irritation at the injection site low-grade fever, weight loss, 
irritability, depression, mild bone marrow suppression, hair loss." (National Digestive, 
2003) Common side effects with Ribavirin include "anemia, fatigue and irritability, 
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itching, skin rash, nasal stuffiness, sinusitis, and cough." (National Digestive, 2003) 
Sometimes the treatment the side effects are worse than the disease. Furthermore not 
everyone is recommended for treatment. Contraindications to interferon therapy include 
"severe depression or other neuropsychiatric syndromes, active substance or alcohol 
abuse, autoimmune disease (such as rheumatoid arthritis, lupus erythematosus, or 
psoriasis) that is not well controlled, bone marrow compromised and inability to practice 
birth control." (National Digestive, 2003) Individuals cannot be treated with Ribavirin if 
they have marked anemia, renal dysfunction, coronary artery or cerebrovascular disease, 
and inability to practice birth control. Individuals may feel overwhelmed to find out that 
they have a disease that may not qualify for treatment because they have an existing 
condition that excludes them from the treatment. 
Health Care Cost Predictions/Economic Impact 
"Although few prospective long-term survival and health care cost studies are 
available for hepatitis C, it has been possible to estimate the life-long economic impact of 
the disease for both the individual patient and for the U.S. population with chronic 
hepatitis B." (C. Everett Koop, 1998) "Lifetime health care costs for a patient with 
chronic hepatitis B has been estimated at $65,000 in the absence of liver transplantation. 
For the 150,000 HBV carriers with significant liver damage, the lifetime health care costs 
in the U.S. have been estimated to be $9 billion. Assuming an estimated survival of 25 
years, the annual health care cost for the affected U.S. population with chronic hepatitis B 
is $360 million. Based on the same economic analysis, treatment of chronic hepatitis B 
with interferon is projected to increase life expectancy by about three years and reduce 
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the aggregate health care costs. (C. Everett Koop, 1998) Hepatitis C infects about 3.5 
more people than hepatitis B. Hepatitis C accounts for one-third of the liver transplants in 
the U.S. The cost per liver transplant is in the range of $280,000 for one year. Liver 
transplantation for hepatitis C (approximately 1,000 HCV patients receive transplants per 
year) alone reaches a cost of nearly $300 million per year. 
"Moreover, the average lifetime cost for hepatitis C, in the absence of liver 
transplant, has been estimated to be about $100,000 for individual patients. 
Assuming that 80% of the 4.5 million Americans believed to be infected develop 
chronic liver disease, the total lifetime cost for this group (3.6 million) will be a 
staggering $360 billion in today' s dollars. Assuming an estimated survival of 40 
years, the annual health care costs for the affected U.S. population with chronic 
hepatitis C may be as high as $9 billion." (C. Everett Koop, 1998) 
According to Wong, Jet a! in the Estimating Future Hepatitis C Mobidity, 
Mortality, and Costs in the United States, "From the year 2010 to 2019, our model 
projected 165,900 deaths from chronic liver disease and 27,200 from hepatocellular 
carcinoma related to hepatitis C." (Wong, McQuillan, McHutchison, & Poynard, 2000) 
"When compared with an age-matched general population over these 10 years, the HCV-
infected cohort would have 959,700 years of decompensated cirrhosis or hepatocellular 
carcinoma and the loss of 3.09 million years of life." (Wong et a!., 2000) "Considering 
those younger than 65, hepatitis C may lead to 720,700 years of decompensated cirrhosis 
and hepatocellular carcinoma and the loss of 1.83 million years of life. (Wong et a!., 
2000) "Over the 10 years from 2010 to 2019, the societal cost of premature mortality for 
those younger than 65 would be $54.2 billion, and the cost of morbidity for disability 
related to decompensated cirrhosis and hepatocellular carcinoma would be $21.3 billion." 
(Wong eta!., 2000) "When only directed medical costs were considered, our model 
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predicted that the cost to treat future HCV-related diseases would range from $6.5 to 
$13.6 billion for the years 2010 though 2019." (Wong eta!., 2000) 
Solomon et al., in their study Cost-effectiveness of Treatment for Chronic 
Hepatitis C Infection in an Evolving Patient Population looked at a cohort of 40 year-old 
men and women with elevated levels of liver enzymes and positive for HCV RNA, and 
no histological evidence of fibrosis on liver biopsy and looked at the cost-effectiveness of 
monotherapy and combination therapy among men and women in terms of lifetime costs, 
life expectancy, quality-adjusted life-years (QALYs), and incremental cost-effectiveness 
ratio. "The probability of patients with chronic HCV developing cirrhosis over a 30 year 
period is from 13% to 46% for men and from 1% to 29% for women. The incremental 
cost-effectiveness combination therapy with pegylated interferon for men ranged from 
$26,000 to $64,000per quality-adjusted life-years (QALY's) genotype 1 and from 
$10,000 to $28,000 per QALY for other genotypes; and for women ranged $32,000 to 
$90,000 for genotype 1 and from $12,000 to $42,000 for other genotypes." (Salomon, 
Weinstein, Hammitt, & Goldie, 2003) Salomon also compared 10 other studies and 
looked at cost-effectiveness of treatment for chronic hepatitis C virus compared with no 
treatment. This is shown in Figure 1 on the next page. 
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Figure 1. Selected Results on the Cost-effectiveness of Treatment for Chronic Hepatitis C Virius (CHCV) Compared with no Treatment 
Interferon Monotherapy 
Study 
Dusheiko et al, 
1995 
Bennett et al, 
1997 
Kim etal, 
1997 
Wong etal, 
1988 
Younossi et al, 
1999 
Shiell et al, 
1999 
Sagmeister et al, 
2001 
30-Year 
Summary of Target Cirrrhosis, 
Population Probability, % t 
25 to 35 years old, CHCV 25(1ow) 
infection, United Kingdom 45(high) 
35 years old, mild CHCV 
infection, United States 
40 years old, CHCV infection, 
United States 
40 years old(mean), mild/ 
moderate CHCV infection or 
cirrhosis, United States 
45 years old,male CHCV 
infection, United States 
40 years old , CHCV 
infection, Australia 
42 years old (mean), mild/ 
moderate CHCV infection, 
genotype 1 , Sweden 
41 
58 
41(mild) 
85(moderate) 
85 
27 
41 (mild) 
85 (moderate) 
~ ' Compared with No Treatment 
Incremental 
QAL Y's Gained CosV 
QALYGained 
Not reported $643-842 
0.083 $1,900 
0.25 $4,000 
0.3 $2,233 
0.095 Cost Savings 
0.32 $4,401 
0.37 $4,579 
Pegylated~lnterferon 
Cbmpared with No Treatm~nt 
QAL Ys Gained 
Not reported 
Not reported 
Not reported 
Not reported 
2.79 
Not reported 
1.12 
Incremental CosU 
QALY 
Not reported 
Not reported 
Not reported 
Not reported 
Cost Savings 
Not reported 
$6,128 
Sennfait et al, 42 years old, mild/moderate 41 (mild) 
2001 CHCV infection or cirrhosis, 85 (moderate) 
genotype 1, Sweden 
Stein et al, Mild/moderate CHCV 41 (mild) 
2002 infection, United Kingdom 85(moderate) 
Wong et al, 43 to 44 years old (mean) 41 (mild) 
2002 CHCV infection, Belgium 85 (moderate) 
Current Study 40 years old, CHCV infection, 30 (men) 
Not reported 
Not reported 
Not reported 
.047 (men) 
Not reported 
Not reported 
Not reported 
$36,300 (men) 
and 
1.10 $5,900 
1.06 $6,129 
1.54 $786 
.361 (men) $29,300 (Men) and 
no fibrosis, genotype 1 , 9 (women) and 0.023 (women) $83,600 (women) and 0.238 (women) $48,000 (Women) 
United States 
Abbreviation: QAL Y, quality-adjusted life year. 
*Some figures have been estimated indirectly to enhance comparability between studies, for example those for which discounted benefits not reported 
Costs were converted to US dollars, where necessary, using official exchange rates. Details available from 
authors. 
t Studies have been used different classifications to model progression from CHCV infection to cirrhosis: (1) direct progression from CHC to cirrhosis 
(2) Progression from mild to moderate CHCV, then cirrhosis; and (3) progression through META VIR stages of fibrosis. 
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Included in the 2003 El Paso County Department of Health of Environment 
Operational Plan for the HIV and Hepatitis C programs, "Center for Disease Control has 
estimated national medical and work-loss costs (excluding transplantation) of HCV 
patients to be over $600 million per year. (Walker, 2003) "In addition, an actuarial firm 
puts total health care costs of those infected with HCV at $15 billion a year." (Walker, 
2003) 
Current Programs In Other States 
A presentation given by Laurie Schowalter at the 2005 Colorado Viral Hepatitis 
& HIV co-Infection conference, Integrating Viral Hepatitis Into Existing Public Health 
Programs: Challenges and Opportunities reveals "Forty-eight states, three cities and the 
Indian Health Services are funded through CDC-DVH for a Hepatitis C Coordinator." 
(Schowalter, 2005) The average funding award is$ 77,000 to integrate with other public 
health programs. Also according to Schowalter "approximately 30 states have completed 
or are in the process of writing a State Hepatitis C/viral hepatitis Plan." (Schowalter, 
2005) CDC lists the States that already have plans in place on their website 
http://www.cdc.gov/ncidod/diseases/hepatitis/partners/state plans.htm. Twenty states are 
listed which included: California, Colorado, Florida, Georgia, Hawaii, Iowa, Louisiana, 
Maine, Maryland, Massachusetts, Minnesota, Nebraska, New Jersey, New Mexico, New 
York, Oregon, Texas, Utah, Washington, & Wisconsin. Oregon also had a plan by 
Multnomah County (Portland, OR), which was included on this site. 
Recommendations for Policy Changes 
The first recommendation for policy change involves the need for more research. 
More focused research is needed so that future program policies can be written. National 
Institutes of Health did identify some important areas in HCV research such as: 
• The development of reliable, reproducible, and efficient culture systems for 
propagating the hepatitis C virus is considered to be of the highest priority. This 
goal is deemed essential not only for vaccine development but also for progress 
in the fundamental aspects of HCV biology, hepatic tropism, and rival 
replication. Furthermore, this development will assist in new drug discovery, as 
well as enhance understanding of the mechanism of drug resistance. 
• The role of genetic factors in the pathogenesis of HCV, including immune 
responses to infection, reasons for spontaneous resolution and variations in 
natural history, and responses to therapy, need further examination. 
• Priority should be given to developing less toxic therapies and molecular-based 
agents that specifically inhibit viral replication and/or translation of Viral RNA. 
• Randomized controlled trials (RCT's) need to be carried out in special 
populations of patients not represented in current trials to determine the 
applicability of currently accepted treatment to these subgroups and the optimal 
doses and duration of therapy. These populations include children, patients with 
acute hepatitis, and patients in drug treatment programs. Research is also needed 
to define the best approaches to treating HCV in active drinkers, prisoners, those 
co-infected with HIV patients with concurrent renal disease and patients with 
major psychiatric illness. 
• Little information exists to describe the natural history of the HCV viremia 
lasting 20 years or more. Studies are needed to examine the pattern of HCV 
disease progression in persons infected for at least two decades, including those 
infected as infants or children. (National Institutes, 2002) 
Much of the current publication use data is based on the National Health and Nutrition 
Examination Survey (NHANES III, 1988-1994), which although was a national phone 
survey it did not include important populations such as incarcerated and homeless which 
hepatitis C has higher concentrations of infected individuals. 
The second recommendation is for the Centers for Disease Control and National 
Institutes of Health to come together and form a universal and clear list of persons that 
need to be tested. When this is done it will help to further focus research, funding, and 
future recommendations. If you look at the risk factors for heart disease they are simple 
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and categorized for the public to understand. The suggestion for high risk would include: 
injection drug users, hemodialysis patients, and recipients of transfusions or organs 
before 1992, those that received unprofessional piercing or tattooing, unsafe medical 
practices, and occupational exposure to infected blood, birth to an infected mother, sex 
with an infected person, high-risk sexual practices, and possibly intranasal cocaine use. 
The third recommendation is to encourage screening of all high risk groups. By 
doing this it will promote a standardization of screening. It will also allow those that are 
infected to be diagnosed earlier and thus allowing for implementation of appropriate 
treatment practices and better quality of care for those diagnosed. Development of testing 
procedures in specialized setting such as public health, correctional settings, drug 
treatment and mental health facilities need to be implemented in multiple communities. 
Many programs must be developed without the appropriate funding available. 
Furthermore, barriers to testing such as cost, lab tum-around times, lack of community 
resources and discrimination need to be addressed so that those at risk can learn their 
status. 
The forth recommendation is to reduce the transmission of HCV. This can be 
done through education of the American public and especially by educating those 
populations at risk. Many public health programs such as needle exchange programs will 
allow intravenous drug users (IDUs) to access sterile syringes. Some of these programs 
are very controversial and need strong data and political support to be implemented in 
may parts of the country. Education of those who work around blood and bodily fluids 
(fire fighters, police, nurses, and physicians, tattoo artists) need to be educated on how to 
protect themselves from exposure and what to do if there is an exposure. Prophylactic 
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treatment needs to also be researched to prevent transmission. More education and 
screening is needed to prevent the transmission of mother-to-infant. 
A firth recommendation is to develop new therapies to current treatment and 
prevention. This will be done witb more research, and will encourage the development of 
a vaccine. The development of the vaccine could prevent thousands from becoming 
infected and would also decrease the rate of liver transplantation. New therapies need to 
be developed to assist those individuals living with hepatitis C and have contraindications 
to current therapies because of other medical conditions such as depression and addiction. 
Another recommendation is to encourage a comprehensive approach to promote 
the collaboration among the many health professionals concerned with the identification, 
management, and treatment of those affected with tbis virus. This disease incorporates 
many professionals including tbose that deal with addiction, primary care physicians, and 
specialist involved with various aspects of dealing with hepatitis C. A comprehensive 
approach is needed to guide those infected through the many providers of care that they 
will encounter through the management of their disease. 
The seventh recommendation is to learn from the lessons learned from HIV I AIDS 
on how to rally politically for funding, services, and standards of care. This will be a 
difficult task to put a political face to the hepatitis C epidemic because it affects all ages, 
all races, and all nationalities. We need those that are infected to tell their stories and how 
this disease has impacted their lives and how it will affect other people's lives. It would 
also be beneficial for those high profile people or celebrities infected with hepatitis C 
would tell their stories so that the American Public can have faces connected to epidemic. 
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It would also be beneficial to create legislation and lobby for this disease and make it part 
of the national health agenda. 
Conclusions 
Hepatitis C is a major public health problem. It is the most common blood born 
pathogen in the United States, making HCV the most common indication for liver 
transplantation. Hepatitis Cis a chronic disease that has treatment. Currently, treatment is 
expensive and time consuming usually lasting 6 months to a year. Although it is still 
unclear why the prevalence of hepatitis C is so high with approximately 4 million being 
infected in the United States we can prevent the incidence of disease with intervention. 
Encouraging education of patients and providers, development of harm reduction 
practices, and testing can improve public health programs. Current recommendations 
from CDC, Nlli, and USPTF are unclear on who is considered high risk and needs 
testing. It also shows that more research is needed. Barriers for those that want to test 
include: demographic, discrimination, ability to access care and treatment, financial, and 
anxiety about lab turn around times. For those who do test positive for hepatitis C there 
are high estimated costs especially with annual health care costs, transplants, disability 
and societal cost to premature mortality, and quality-adjusted life-years. Although 
approximately 30 states have completed or in the process of completing a viral hepatitis 
plan there needs to be national recognition planning and funding to lesson the morbidity 
and mortality associated with hepatitis C in this country. 
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